Nyxoah SA (NYXH) Analyst/Investor Day Transcript

My name is Elisa, and I'll be your moderator for today's call. [Operator Instructions] I would now like to pass the conference over to our host, Olivier Taelman, CEO of Nyxoah. You may proceed. Olivier Taelman CEO & Executive Director [Audio Gap] Nyxoah because as you most likely all have seen, we yesterday published our Q1 preliminary numbers. And I can tell you there is a lot of excitement inside of the company, and we will walk you through all of the details during the day. If we go through the agenda, as you can see, it's quite a busy agenda, and we also hope that we will be able to provide you with a lot of insights on where we stand, but also most important on where we are going and what you can expect. We will start by having some of our leading physicians talking about their experience. Afterwards, we will address the hot potato in hypoglossal nerve stimulation, reimbursement. Also there, we were able to have an expert panel in the U.S., reimbursement experts, the JD Lymon Group. Then we will focus a little bit more about Nyxoah and where we stand, how do we see the market dynamics because there is also a lot of activity